Quris Technologies Ltd. (Quris-AI) and Merck KGaA have extended their collaboration after a successful initial preclinical study of Quris-AI’s BioAI drug safety platform.

Quris Technologies Ltd. has inked an agreement with Merck KGaA to assess its BioAI safety prediction platform. The partnership will compare the Quris’ artificial intelligence (AI)-based platform with traditional in vivo and in vitro approaches of evaluating drug safety concerns.